PMID- 30633211
OWN - NLM
STAT- MEDLINE
DCOM- 20190121
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 2
DP  - 2019 Jan
TI  - Malignant perivascular epithelioid cell tumor in the female genital tract: 
      Preferred reporting items for systematic reviews and meta-analyses.
PG  - e14072
LID - 10.1097/MD.0000000000014072 [doi]
LID - e14072
AB  - BACKGROUND: Perivascular epithelioid cell tumor (PEComa) is a rare mesenchymal 
      tumor, located at various anatomic sites, including the female genital tract. 
      This study aimed to evaluate the clinicopathological characteristics of patients 
      with PEComa arising from the female genital tract. METHODS: A retrospective study 
      was conducted in Taipei Veterans General Hospital (Taipei VGH) between 2008 and 
      2018. All published English cases based on the Preferred Reporting Items for 
      Systematic Reviews and Meta-Analyses (PRISMA) statement were also included in the 
      current review. RESULTS: A total of 114 women from PRISMA and 3 women from Taipei 
      VGH were identified. The uterus was the most commonly involved site (82/114, 
      71.9%), followed by the cervix (12/114, 10.5%). Immunohistochemical staining 
      showed that nearly all gynecological PEComas were positive for human melanoma 
      black 45 (113/114, 99.1%). More than half of the gynecological PEComas were 
      immunoreactive for desmin (50/85, 58.8%). Multi-modality treatment, including 
      surgery and mammalian target of rapamycin (mTOR) inhibitors as targeted therapy, 
      provided long-term disease-free survival (cure rate ranging from 50% to 100%, 
      based on the different anatomic sites of the female genital tract). CONCLUSION: 
      Multi-modality treatment, including cytoreductive surgery and mTOR inhibitors 
      with/without chemotherapy and/or radiation, should be considered for the 
      management of women with PEComas in the genital tract.
FAU - Liu, Chia-Hao
AU  - Liu CH
AD  - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital.
AD  - Institute of Clinical Medicine, National Yang-Ming University.
AD  - Department of Obstetrics and Gynecology, National Yang-Ming University.
FAU - Chao, Wei-Ting
AU  - Chao WT
AD  - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital.
AD  - Department of Obstetrics and Gynecology, National Yang-Ming University.
AD  - School of Medicine, Fu-Jen Catholic University, New Taipei City.
FAU - Lin, Shih-Chieh
AU  - Lin SC
AD  - Institute of Clinical Medicine, National Yang-Ming University.
AD  - Department of Pathology and Laboratory Medicine, Taipei Veterans General 
      Hospital, Taipei.
AD  - School of Medicine, National Defense Medical Center, Taipei.
FAU - Lau, Hei-Yu
AU  - Lau HY
AD  - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital.
AD  - Department of Obstetrics and Gynecology, National Yang-Ming University.
AD  - School of Medicine, China Medical University, Taichung.
FAU - Wu, Hua-Hsi
AU  - Wu HH
AD  - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital.
AD  - Department of Obstetrics and Gynecology, National Yang-Ming University.
AD  - School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
FAU - Wang, Peng-Hui
AU  - Wang PH
AD  - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital.
AD  - Institute of Clinical Medicine, National Yang-Ming University.
AD  - Department of Obstetrics and Gynecology, National Yang-Ming University.
AD  - Department of Medical Research, China Medical University Hospital, Taichung.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Combined Modality Therapy
MH  - Female
MH  - Genital Neoplasms, Female/*diagnosis/pathology/therapy
MH  - Humans
MH  - Middle Aged
MH  - Perivascular Epithelioid Cell Neoplasms/*diagnosis/pathology/therapy
PMC - PMC6336598
COIS- The authors declare that they have no competing interests.
EDAT- 2019/01/12 06:00
MHDA- 2019/01/22 06:00
PMCR- 2019/01/11
CRDT- 2019/01/12 06:00
PHST- 2019/01/12 06:00 [entrez]
PHST- 2019/01/12 06:00 [pubmed]
PHST- 2019/01/22 06:00 [medline]
PHST- 2019/01/11 00:00 [pmc-release]
AID - 00005792-201901110-00062 [pii]
AID - MD-D-18-06863 [pii]
AID - 10.1097/MD.0000000000014072 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Jan;98(2):e14072. doi: 10.1097/MD.0000000000014072.